Why don’t doctors use early insulinization therapy in patients with diabetes mellitus type 2?: A qualitative approach in a Mexican city

Roberto Lagunes Córdoba; Isaac Galindo Guevara; Atalia Castillo Reyes; Citlalli Romero Aparicio; Francisco Javier Rosas Santiago

doi:10.18294/sc.2017.1341

Why don’t doctors use early insulinization therapy in patients with diabetes mellitus type 2?: A qualitative approach in a Mexican city

Roberto Lagunes Córdoba PhD in Science. Full-time researcher, Institute of Psychological Research, Universidad Veracruzana, Veracruz, Mexico. , Isaac Galindo Guevara Undergraduate Degree in Psychology. Postgraduate Degree in Opinion Surveys in progress, Faculty of Psychology, Universidad Veracruzana, Veracruz, Mexico. , Atalia Castillo Reyes Master’s Degree in Public Health. PhD in Psychology in progress, Institute of Psychological Research, Universidad Veracruzana, Xalapa, Veracruz, Mexico. , Citlalli Romero Aparicio Undergraduate Degree in Psychology. Fellowship, Faculty of Psychology, Universidad Veracruzana, Xalapa, Veracruz, Mexico. , Francisco Javier Rosas Santiago PhD in Science. Full-time researcher, Institute of Psychological Research, Universidad Veracruzana, Xalapa, Veracruz, Mexico.

Received: 4 March 2017, Accepted: 30 May 2017, Published: 14 December 2017

https://doi.org/10.18294/sc.2017.1341

Abstract views

1978

Metrics Loading ...

PDF (Español)

PDF

Abstract

Early insulinization therapy is regarded as an efficient aid to improve long term control and quality of life in patients with diabetes mellitus type 2 (DM2). Nevertheless, both patients and medical staff confront barriers in using this therapeutic tool. This study employs a qualitative approach to explore the barriers to early insulinization among medical staff from the public sector in the city of Xalapa, Veracruz, México. Between 2015 and 2016, in-depth interviews were conducted with general and specialist physicians offering primary health care to patients with DM2. The transcribed interviews were analyzed to extract and organize categories and subcategories of barriers among medical staff. These barriers were then grouped into three categories and exemplified with interview excerpts: barriers coming from the medical staff itself, barriers emerging from the doctor-patient interaction, and institutional barriers. Uses for the classification obtained are discussed, as are some of the solutions proposed by study participants.

Keywords: Diabetes Mellitus Type 2, Hospital Medical Staff, Therapeutics, Mexico

Categories: Healthcare models

References

1. Escobar MC. Mitos sobre la prevención de las enfermedades no transmisibles en América Latina. Salud Pública de México. 2000;42:56-64.

2. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014;37(Suppl 1):S81-S90.

3. World Health Organization. Diet, nutrition and the prevention of chronic diseases. (World Health Organ Technical Report Series No. 916). Washington: WHO; 2003.

4. Organización Mundial de la Salud. Informe mundial sobre diabetes: Resumen de orientación [Internet]. 2016 [citado 19 ene 2017]. Disponible en: https://goo.gl/DYwZs7

5. Hernández-Ávila M, Gutiérrez J, Reynoso-Noverón N. Diabetes mellitus en México: El estado de la epidemia. Salud Pública de México. 2013;55(Suppl 1):S129-S136.

6. Villalpando S, De la Cruz V, Rojas R, Shamah-Levy T, Ávila MA, Gaona B, Rebollar R, Hernández L. Prevalence and distribution of type 2 Diabetes mellitus in Mexican adult population: A probabilistic survey. Salud Pública de México. 2010;52(Suppl 1):S19-S26.

7. Rull JA, Aguilar-Salinas CA, Rojas R, Ríos-Torres JM, Gomez-Perez FJ, Olaiz G. Epidemiology of type 2 diabetes in México. Archives of Medical Research. 2005;36:188-196.

8. García-Soto CE. El costo de vivir con diabetes. Brújula de Compra [Internet]. 2007 [citado 19 ene 2017]. Disponible en: https://goo.gl/BL13cJ

9. Gómez-Dantés O, Sesma S, Becerril VM, Knaul F, Arreola H, Frenk J. Sistema de salud en México. Salud Pública de México. 2011;53(Supl 2):S220-S232.

10. Instituto Nacional de Estadística, Geografía e Informática. Número de habitantes de Veracruz [Internet]. 2015 [citado 19 ene 2017]. Disponible en: https://goo.gl/U1g4QR

11. Standards of Medical Care in Diabetes. Glycemic targets. Diabetes Care. 2016;39(Suppl 1):S39-S46.

12. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 2009;52:17-30.

13. Menéndez TE, Lafita TFJ, Artola MS, Millán NCJ, Alonso GA, Puig DM, García SJR, Álvarez GF, García AJ, Mediavilla BJ, Miranda FC, Romero GR. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Endocrinology and Nutrition. 2011;58:112-120.

14. National Institute for Health Care Excellence. Algorithm for blood glucose lowering therapy in adults with type 2 diabetes [Internet]. 2015 [citado 23 may 2017]. Disponible en: https://goo.gl/QmjHY8

15. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach; update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetología. 2015;58(3):429-442.

16. Asociación Latinoamericana de Diabetes. Guías ALAD sobre el diagnóstico, control y tratamiento de la Diabetes Mellitus tipo 2 con medicina basada en evidencia [Internet]. 2013 [citado 23 may 2017]. Disponible en: https://goo.gl/RE8LVu

17. Müssig K. [Insulin therapy: as early as possible]. Deutsche Medizinische Wochenschrift. 2016;141(8):578-579.

18. Hanefeld M, Bramlage P. Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Current Diabetes Reports. 2013;13:342-349.

19. Sorli C. Insulin therapy in type 2 diabetes: a reflection on the state of the art today, and the potential journeys yet to come. American Journal of Medicine. 2014;127(Suppl 1):S1-S2.

20. Lovre D, Fonseca D. Benefits of timely basal insulin control in patients with type 2 diabetes. Journal of Diabetes Complications. 2015;29:295-301.

21. Lerman I, Moreira-Díaz JP, Romero-Ibarguengoitia ME, Gómez-Pérez FJ. Reluctance to insulin therapy in low-income, type 2 diabetic patients: the need for stronger reinforcement strategies. Endocrine Practice. 2009;15:41-46.

22. Vinagre I, Conget I. Control of type 2 diabetes mellitus in Spain today: identification of the main obstacles in daily clinical practice. Medicina Clínica. 2013;144(Suppl 2):S3-S6.

23. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. New England Journal of Medicine. 2002;347:1342-1349.

24. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. The Diabetes Educator. 2006;32(Suppl 1):S9-S18.

25. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L, International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.

26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.

27. Polonsky WH, Fisher L, Guzmán S, Villa-Caballero L, Edelman, SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-2545.

28. Hunt LM, Pud A, Valenzuela M, Ba A, Pugh J. NIDDM Patients’ Fears and Hopes About Insulin Therap. Diabetes Care. 1997; 20: 294-298.

29. Karter AJ, Parker MM, Swain BE, Moffet HH, Subramanian U, Saha C. Barriers to Insulin Initiation. The Translating Research Into Action for Diabetes Insulin Starts Project. Diabetes Care. 2010;33:733-735.

30. Bogatean MP, Hancu N. People with type 2 diabetes facing the reality of starting insulin therapy: factors involved in psychological insulin resistance. Practical Diabetes International. 2004;21:247-252.

31. Oliveria SA, Menditto LA, Yood MU, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Current Medical Research and Opinion. 2008;23:3105-3112.

32. Lee YK, Lee PY, Ng CJ. A qualitative study on healthcare professionals’ perceived barriers to insulin initiation in a multi-ethnic population. BMC Family Practice. 2012;13:28. Doi: 10.1186/1471-2296-13-28.

33. Lerman I. Barreras que dificultan la aplicación temprana de insulina en el paciente con diabetes tipo 2. ALAD Asociación Latinoamericana de Diabetes. 2009;XII(2):66-68.

34. Polinski J, Smith B, Curtis B, Seeger J, Choundhry N, Connolly J, Shrank W. Barriers to insulin progression among patients whit type 2 diabetes: a systematic review. Diabetes Educator. 2013;39(1):53-65.

35. Ávalos-García M, López-Ramón C, Priego-Álvarez H, Córdova-Hernández A, Morales-García M. Barreras y perspectivas del personal de salud en el control de la diabetes mellitus en unidades médicas de la seguridad social de Tabasco: Un estudio cualitativo. Horizonte Sanitario. 2013;12(3):111-119.

36. Estados Unidos Mexicanos. Norma Oficial Mexicana NOM 015-SSA2-2010 Para la la prevención, el control y el tratamiento de la diabetes mellitus [Internet]. 2010 [citado 6 feb 2017]. Disponible en: https://goo.gl/TGyuSw

37. Subsecretaría de Integración y Desarrollo del Sector Salud. Modelo de atención integral de salud (MAI): Documento de arranque [Internet]. 2015 [citado 6 feb 2017]. Disponible en: https://goo.gl/xshJgX

38. Jiménez-Corona A, Aguilar-Salinas CA, Rojas-Martínez R, Hernández-Ávila M. Diabetes Mellitus tipo 2 y frecuencia de acciones para su prevención y control. Salud Pública de México. 2013;55(Supl 2):S137-S143.

39. Álvarez-Gayou JJL. Cómo hacer investigación cualitativa: Fundamentos y metodología. México: Paidós Educador; 2003.

40. Martínez-Salgado C. El muestreo en investigación cualitativa: principios básicos y algunas controversias. Ciȇncia & Saúde Coletiva. 2012;17(3):613-619.

41. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Education Today. 2004;24:105-112.

42. Hernández SR, Fernández CC, Baptista LP. Metodología de la investigación. 6a ed. México: Mc Graw Hill Education; 2014.

43. Eldeman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. American Journal of Medicine. 2014;127(Suppl):S11-S16.

44. Peyrot M, Rubin RR, Khunti K. Adressing barriers to initiation of insulin in patients whit type 2 diabetes. Primary Care Diabetes. 2010;4(Suppl 1):S11-S18.

45. Lara y Mateos RM. Medicina y cultura: hacia una formación integral del profesional de la salud. 2a ed. México: El Manual Moderno; 2005.

46. Barsky AJ. The paradox of health. The New England Journal of Medicine. 1988;318(7):414-418.

47. Castro R. La vida en la adversidad: el significado de la salud y la reproducción en la pobreza. México: CRIM/UNAM; 2000.

48. Trujano R, Vega Valero Z, Nava Quiroz C, Saavedra Vásquez K. Interacción médico-paciente y su relación con el control del padecimiento en enfermos crónicos. Liberabit. 2011;17(2):223-230.

49. Escudero-Carretero MJ, Prieto-Rodríguez M, Fernández-Fernández I, March-Cerdà J. La relación médico-paciente en el tratamiento de la diabetes tipo 1: Un estudio cualitativo. Atención Primaria. 2006;38(1):8-18.

50. Martín L, Grau J. La investigación de la adherencia terapéutica como un problema de la psicología de la salud. Psicología y Salud. 2004;14(1):89-99.

51. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clinical Therapy. 2011;33(1):74-109.

52. Brunton SA, Polonsky WH. Medication adherence in type 2 diabetes mellitus: real-world strategies for addressing a common problem. The Journal of Family Practice. 2017;66(Suppl 4):S46-S51.

53. Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Quarterly. 2001;79(4):613-639.

54. Keating NL, Gandhi TK, Orav EJ, Bates DW, Ayanian JZ. Patient characteristics and experiences associated with trust in specialist physicians. Archives of Internal Medicine. 2004;164(9):1015-1020.

55. Fiscella K, Meldrum S, Franks P, Shields CG, Duberstein P, McDaniel SH, Epstein RM. Patient trust: is it related to patient-centered behavior of primary care physicians? Medical Care. 2004;42(11):1049-1055.

56. Duberstein P, Meldrum S, Fiscella K, Shields CG, Epstein RM. Influences on patients’ ratings of physicians: Physicians demographics and personality. Patient Education Counseling. 2007;65(2):270-274.

57. Cassel EJ. The Healer´s Art: A new approach to the doctor-patient relationship. New York: Lippincot; 1976.